To clarify the change in characteristics and body mass index standard deviation (BMI-SD) after guanfacine extended-release (GXR) administration for attention-deficit/hyperactivity disorder (ADHD) children, we undertook a clinical survey of ADHD children. Methods:Among 209 pediatric patients with ADHD, two groups were selected:those who patients were received GXR monotherapy (Group 1) and those who were treated with non-pharmacological therapy alone (Group 2). Results:1) BMI-SD scores before and…
